Effects of 4-Hydroxyandrostenedione in Advanced Breast Cancer
Author Information
Author(s): T. Pickles, L. Perry, P. Murray, P. Plowman
Primary Institution: St Bartholomew's Hospital, London
Hypothesis
Does 4-Hydroxyandrostenedione (4-OHA) effectively treat postmenopausal women with advanced breast cancer who have failed other endocrine therapies?
Conclusion
The study found that 4-OHA was clinically effective, achieving a response rate of 39% with a mean duration of response of 8 months.
Supporting Evidence
- Seven out of 18 assessable patients (39%) responded to the treatment.
- The mean duration of response was 8.2 months.
- Significant falls in oestradiol and oestrone levels were observed initially.
- SHBG levels gradually fell during the study, indicating some androgenic activity.
Takeaway
This study tested a drug called 4-OHA on women with advanced breast cancer, and it helped some of them feel better for several months.
Methodology
The drug was administered intramuscularly every two weeks to postmenopausal women with advanced breast cancer, and various endocrine measurements were taken throughout the study.
Potential Biases
Potential bias due to the lack of a control group and the subjective nature of some assessments.
Limitations
The study had a small sample size and some patients were not assessable due to withdrawals.
Participant Demographics
Postmenopausal women aged 46 to 85, with a mean age of 65.
Statistical Information
P-Value
0.02 for oestradiol, 0.012 for oestrone, 0.0012 for cortisol, 0.03 for SHBG
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website